Text Size

Surveillance of Summer Febrile Syndromes of Viral Origin in South of France

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2010 by Assistance Publique Hopitaux De Marseille.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Assistance Publique Hopitaux De Marseille
ClinicalTrials.gov Identifier:
NCT00842166
First received: February 11, 2009
Last updated: May 18, 2010
Last verified: May 2010
History of Changes
  Purpose

The aim is to document viral etiologies of isolated fevers and inlfuenza-like syndromes during summertime in South of France in order to better understand the role of known vector-borne viruses such as Toscana virus, West Nile virus during seasonal activity of the arthropod vector. In each of the four cities, a network of general practitioners will be associated in the project to recruit patients who are not hospitalized. The combined involvement of infectious disease specialists and general practitioner will augment the range of patients (mild disease and sever cases) in the study.


Condition Intervention
Summer Febrile Syndromes of Viral Origin
 Other: BLOOD DRAW

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention

Resource links provided by NLM:

MedlinePlus related topics: Fever
U.S. FDA Resources

Further study details as provided by Assistance Publique Hopitaux De Marseille:

Primary Outcome Measures:
  • to document viral etiologies of isolated fevers and inlfuenza-like syndromes during summertime in South of France [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Identification and characterization of emergent viruses responsible for estival fever in the south of France [ Time Frame: 3years ] [ Designated as safety issue: No ]

Estimated Enrollment: 900
Study Start Date: February 2009
Estimated Study Completion Date: August 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: BLOOD DRAW
    specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
  Eligibility

Ages Eligible for Study:   5 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Old: equal to or higher than 5 years Living in the south of France, without voyage abroad in the 2 weeks preceding inclusion Presenting a fever or a syndrome pseudogripal since less than 7 days without diagnostic orientation nor infectious pathology of body,
  • Affiliated with a mode of social security
  • After obtaining free and informed of the written assent

Exclusion Criteria:

  • Subject whose adhesion with the protocol is improbable according to the investigator
  • Expectant mother
  • Subject taking part in another clinical trial or in period of exclusion of a preceding clinical trial infectious
  • Pathology of body requiring a specific treatment
  • Discovered after inclusion d' a pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00842166

Locations
France
Service des Maladies Infectieuses et Tropicales de l'Hôpital Nord, AP-HM Recruiting
Marseille, France
Contact: Rémi Charrel     0491986477     remi.charrel@ap-hm.fr    
Principal Investigator: remi CHARREL            
Sponsors and Collaborators
Assistance Publique Hopitaux De Marseille
Investigators
Principal Investigator: REMI CHARREL Assistance Publique Hopitaux De Marseille
  More Information

No publications provided

Responsible Party: Assistance Publique-Hôpitaux de Marseille, Assistance Publique des Hopitaux de Marseille
ClinicalTrials.gov Identifier: NCT00842166     History of Changes
Other Study ID Numbers: 2008 19, 2008-A00793-52
Study First Received: February 11, 2009
Last Updated: May 18, 2010
Health Authority: France: Ministry of Health

Additional relevant MeSH terms:
Fever
Body Temperature Changes
Signs and Symptoms

ClinicalTrials.gov processed this record on May 16, 2013